Adjuvant Formulation for Companion Animals Vaccines  by Deville, S. et al.
doi:10.1016/j.provac.2011.07.015
Procedia in Vaccinology 4 (2011) 104–112
Available online at www.sciencedirect.com
4th Vaccine and ISVAnnual Global Congress
Adjuvant Formulation for Companion Animals Vaccines
S. Devillea*, E. Carneauxa, F. Bertranda, S. Cauchardb, J. Cauchardb, L. Dupuisa
aSEPPIC Tour Kupka C, 7 Boulevard Franck Kupka 92039 Paris La Défense Cedex France
bANSES, Laboratoire de pathologie équine de Dozulé14 430Goustranville
Abstract
Companion animals are sensitive species able to strongly react to vaccine. Compared to farmanimals, owner’s
sensibility to vaccine safety is exacerbated due to emotional links between animal and owner. Adjuvant selection
during vaccine development is a key parameter driving vaccine safety and efficacy profile. Our studies demonstrated
the ability to use Montanide PetGel A (polymeric adjuvant manufactured under GMP rules) in cat, dog and horse
vaccines. Adjuvants performances were highlighted by local and general safety parameters but also through vaccine
efficacy to trigger a protective immune response against the pathogen. Three trials were performed to validate
Montanide PetGel A compatibility with cats, dogs and horses vaccine models. Experimental vaccines were
formulated using different antigens according to the animal: inactivated Rhodococcus equi (horse), purified
ovalbumin (cat) Leptospira Icterohaemorrhagiae (dogs). In all trials, safety was followed through behavior and
temperature measurement. Furthermore, in dog and cat models, histology studies were performed to assess the local
reaction in the injection site. A kineticofblood sampling was performed in all trials. Antigen specific ELISAwas
used to assess the immune response induced. In cat and dog trials, aluminiumbased formulation were used as
benchmark for Montanide formulationwhile in horse we compare Montanide Pet Gel A based vaccine to an
already published internal reference. Safety performances ofMontanide Pet GelA were superior to aluminium
based vaccines in dogs and cats. Transient oedemas were observed in horse vaccine model after each vaccine
injection, nevertheless, no impact on the animal behaviorwas observed. The antibodies production induced by
Montanide PetGel A based vaccineswas higher than aluminiumbased vaccines or internal reference.
Montanide Pet Gel A can be used associated with a wide range ofantigenic media and recommended to be used as
adjuvant for sensitive animal’s vaccines.
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1. Introduction
Adjuvants technologies dedicated to veterinary sensitive species are mainly aluminium salts [2, 3]. The
other main technologies used in veterinary vaccines are emulsifi ed oil based formulations. Those types of
formulations are poorly compatible with the safety expectation of pet’s models. Indeed, added to the
animal sensitivity to vaccine injections [4], the emotional links between the animals and it’s owner lead to
a perfect safety profile expectations: no local or general reactions would be tolerated in companion
animals. Aluminium salts are sometimes considered as a reference in term of safety and are used in most
of the more sensitive species because of their safety profile [11]. Nevertheless, aluminium salts are known
to induce aTH2 profile and poor long lasting immune response [1]. New adjuvant generation is therefore
needed, presenting an equivalent safety profile, compared to aluminium salts adjuvant but inducing a
better immune stimulation. To answer this question a new adjuvant based on a dispersion of a high
molecular weight polyacrylic polymer was created. Produced under GMP like conditions, this sterile
adjuvant is a dispersion of highly stable calibrated spheric micronic gel particles of sodium polyacrylate
in water [15]. This polymeric technology, Montanide Gel, has already been used in several vaccine
models, including pet’s vaccines, with a promising safety and efficacy profile [6, 12, 13]. Our findings
highlight the safety and efficacy profile of this polymer based adjuvants dedicated to species where
vaccine safety is sometimes of higher importance than efficacy. We present data collected in pets models
(dog and cat) as well as horse model.
2. Material and methods
2.1 Dog model
Dogs were 6 months old male and female cross breed animals. Ten animals were randomly introduced in
each group. Montanide PET GEL A was used in this field trial at a final concentration of 5%. As a
positive control a commercial aluminium based vaccine was used. All vaccines were containing the same
amount of antigenic media. The bacterial antigen was kindly provided by ROMVAC Company (Romania,
2007). It was an inactivated culture of Leptospira Icterohaemorrhagiae. Vaccine safety was recorded
during the trial by the palpation of the injection site. Temperature of all animals was recorded during 3
days after each injection. Animal behaviour (social, food intake) was also followed during the same
period. At the end of the trial on day 120, a subcutaneous biopsy was performed at the injection site on
each animal. All biopsy were performed under anaesthesia and analyzed through Hemalun Eosin Safran
coloration (HES). This work was performed by IDEXX Alfort laboratories (Al fortville, France). This
speci fic coloration of samples allows the identification in the injection site of all cell populations present
as well as necrosis, fibrosis and vaccine remnants. Blood samples were collected every week and sera
extract ed from blood submitted to antigen specifi c ELISA.
2.2 Cat model
Fifteen European healthy cats, from 1 to 4 years old, untreated with any medication from 2 month before
the day of first vaccination, were randomly separat ed in three groups of five animals. During all the trial,
animals were kept in collective cage and with water adlibitum. Food was individually distributed and
weighed to assess the impact of vaccination on appetite of the animals. Table 1 hereunder presents the
vaccines tested in this trial.
Table1: Cat trial vaccine composition per dose of 1ml.
Group Adjuvant % Antigen μg
Montanide
Pet Gel A
7,5
Aluminium salt 2
Control No adjuvant
100μg / dose
106  S. Deville et al. / Procedia in Vaccinology 4 (2011) 104–112
Vaccines were injected twice 21 days apart. Vaccines were injected subcutaneously in the neck; a volume
of 1ml was delivered at each injection. The safety of the tested vaccines was assesses by observation
during all the trial of the animal behaviour, food consumption and body temperature. The local safety was
assessed by observation and handling of the injection site 24, 48, 72, 96 and 120h and a biopsy of the
subcutaneous tissues on day 44 post first injection. Efficacies of the vaccines were assessed trough a
kinetic of blood sampling (D-1 then day 7, 20, 29, 36 and 44). Antigen specifi c ELISA was performed to
detect the OVA speci fic IgG induced by vaccination.
2.3 Horse model
Female horses aged from one to seven years old were randomly inserted in two groups (twenty animals’
for adjuvanted vaccine and ten for control group). Antigen was kindly provided by ANSES (Dozulé,
France). This antigen was composed of proteins from Rhodococcus equi. Vaccine administration was
done by intramuscular injection of 1 ml of vaccine in the neck at day 0 and day 28. Table 2 hereunder
describes the vaccine composition. Following each injection the animals were observed during three days.
Vaccine safety was recorded by palpation of the injection site and rectal temperature of all animals was
also recorded. Animal behaviour (social, food intake) was followed during the same period.
Table2: Horse vaccine composition per dose of 1 ml.
Group Adjuvant % Antigen mg
Montanide
Pet Gel A
10
Control No adjuvant
0.5mg
2.4 Antigen specific ELISA detection of IgG subclasses
ELISA method was used in all trials to assess the level of immunoglobulins induced in the vaccinated
animal sera. The protocol was similar for all animals; Only the detection antibody was selected to have
species speci ficity. Detection antibodies used in our trials are Sheep anti-dog IgG:HRP (AAI32P) for dog
IgG detection, Mouse anti-cat IgG (MCA2651) for cat IgG detection. OVA (cat model), Leptospira (dog
model) was added in ELISA plate (Nunc Maxisorp, ref 055133) and incubated at 37°C for 2 hours. The
plates were then washed with PBS / Montanox 20 (Polysorbate20, SEPPIC) 0.05%. After three
washings, the plates were incubated with 200μl of blocking solution (5% swine gelatin, Prolabo), 0.05%
Montanox 20 in PBS) for 30 min at 37°C. Amouse serum containing an IgG1 antibody high titre and
diluted 1/1000 in blocking solution and was added (100μl). Plates were incubated for 1h at 37°C and
washed 3 times. Species speci fic detection antibody was diluted 1/6000 in blocking solution was added
(100μl) and the plates were incubated for 1h at 37°C. The peroxidase activity was visualized withTMB
(100μl) (ZYMED), stopped with 50μl of H2SO4 (12.5%). The optical density (OD) was read at 450nm.
OD quantifies the amount of IgG subclasses presents in the animal’s sera.
3. Results
No modification of the animal behaviour was detected (social, food intake…) whatever the model.
3.1 Dog model
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No impact of the vaccine delivery was observed on the body temperature of dogs whatever the vaccine
group. Mild and transient oedemas were observed during the trial, mainly after the booster injections. All
reactions observed were of the same type: small oedemas and swelling of the injected site (less than 2
cm²). The duration of the local reactions at the injection site was dependant of the adjuvant. All reactions
were observed only 48 hours after injection for the first vaccine delivery (data not shown). But for the
booster injection the reactions appeared 24 hours aft er injection, for both aluminium andMontanide
PET GEL A based formulation, but lasted until 72 hours for Montanide PET GEL A and more than 144
hours for aluminium based vaccine. None of the dog receiving the antigen in saline presented reactions at
the injection site. HES coloration performed on biopsy sampled on day 120 gave a higher rate of local
reactions for the Montanide based vaccine compared to the aluminium based formula. Six out of the ten
animal’s injected presented reactions for the Montanide PET Gel A based vaccine while only two out
of ten for the aluminium formula. Pictures 1 and 2 presents local reactions from Montanide injected
dogs. Fibrosis as well as a strong infiltration ofmonocytes can be observed in the injected site. No
vaccine remnants and no necrotic tissues were observed in the samples from that vaccine groups. On the
opposite, only two animals (Pictures 3 and 4) presented reactions for the aluminium based vaccine but
both of those reactions included necrotic tissues and large granulomas. Those two kinds of reaction were
also associated with fibrosis as well as a strong infiltration ofmonocytes.
Picture 1, 2, 3, 4: a: necrotic tissues, b: granulomas, c: fibrosis, d: normal tissue. Local reaction observed in
subcutaneous tissuebiopsies performed in dog 120 days after first injection of several vaccines. Pictures 1 and 2
presents reactions examples induced by Montanide GEL PETA based formula while pictures 3 and 4 presents
reactions observed with vaccines based on aluminium.
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3 4
a
a
b
C
C
C
C
d
d
108  S. Deville et al. / Procedia in Vaccinology 4 (2011) 104–112
Figure 1 presents the seroconversion rates observed all along the trial. All titers detected were above the
protective threshold (data not shown).
Figure 1:seropositivedogs to Leptospira antigens at each sampling date.
As presented in Figure 1, only the Montanide PET GEL A could induce 100% of dogs to be
seroconverted at D84 and up to the end of the trial. Vaccines containing aluminium salts as adjuvant
induced only 60% of seroconversion at D84 and presented a decreased percentage at D120.
3.2 Cat model
Vaccine tested had no significant impact on the rectal temperature of animals. Histological data collected
in our cat model confirmed the reduced infl ammatory reaction induced by the Montanide adjuvant
compared to the aluminium formula. Indeed the booster injection induced 100% of necrosis in the
subcutaneous tissue with alum while only 40% of the animals presented such reaction with the
Montanide Pet Gel A based formulation. Nevertheless, the reactions observed are limited in size and
have no impact on the local macroscopic safety: no irritation of the skin could be observed with any of the
tested vaccine.
Pictures 5 to 13: Local reactions observed in subcutaneous tissuebiopsies performed in cats after injection of
vaccines based on aluminium salts or Montanide PETGEL A. Reactions are observed at threedifferent
magnitude: X4 to X40.
As observed in the picture 7, 10 and 13, no reactions could be observed following injection of antigen in
saline buffer for the control group. The picture shows a normal subcutaneous tissue section for all
animals. Pictures performed on colored cuts from biopsies of animals injected with the adjuvanted
vaccines shows a different profile as a strong inflammatory process can be observed. At different
X40
X10
X4
ControlMont anide  Pet Gel A 7.5%Al uminium salts 2%
5 6 7
8 9 10
11 12 13
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magnifi cation we observe an intense infiltration of the injection site by monocytes and macrophages for
the both adjuvanted formulation. Fibrosis can be observed only for Montanide based formulation
indicating a faster onset of healing activity with this experimental vaccine. Numerous lymphocytes were
indentified in the samples of animals injected with Montanide but we were not able to compare if that
infiltration was significantly higher compared to the aluminium salts induced lymphocyte attraction.
Some adjuvant remnants can still be observed in the tissue sections for aluminium salts and Montanide
Pet Gel A based formulations as biopsies were performed only 23 days aft er the booster injection.
Figure 2 presents antibody titres in cat sera induced after injection SCof various cat experimental formulations.
Results are means of individuals ELISAmeasurements.
The last sampling of the trial was performed on day 43 in order to reduce the animal stress (biopsies were
performed on day 44). No significant differences were observed between the alum based formulation and
the Montanide Pet Gel A one. Nevertheless, the Montanide based vaccine induced a stronger
immune response in all except one animal from that group. Both of the adjuvanted vaccines induced a
significantly stronger response compared to the control group.
3.3 Horse model
After the first injection horse’s body temperature increased of 1°C in both groups while at the booster
injection only the adjuvanted formula induced an increased temperature of 1°C. Nevertheless this raise of
temperature had no impact on the animal behaviour. Local reactions observed were oedemas: those
reactions were transient but last one week on some individual. The adjuvant presence in the vaccine
formulation increased the size of the reactions in all animals, but not the duration Table 3 hereunder
present the size in centimetre square of the local reactions observed in the injection site area (cumulated
scores of 20 animals). None of the reactions observed moved from oedemas to sterile or infectious
abscesses and no medication was needed.
Table3 :Cumulative scoring of local reactions observed after booster injection of vaccines (Montanide group:
n=20; control group n=10). Individual scoring was defined according to thereaction size in cm²: less than
10cm²=1 ; 10 to 20 cm²=2 ; more than 20cm²=3.
T0 D1 D2 D3 D4 D5
Montanide 0 14 24 24 18 1
Antigen 0 3 11 4 2 2
Differences observed were signifi cant, neverthel ess all reactions observed were transient and not related
to modification of animal behaviour. We considered the animal wel fare or economical performance as
unmodified by the vaccines tested.
AlOh 2% Pet Gel A 7.5% Antigen in saline
Antigen specific IgGkinetic.
100
1000
10000
100000
D0 D7 D20 D29 D37 D43
days post injection
tit
re
s
tit
re
s
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4. Discussion
Three trials performed in target animal as well as the pre-clinical studies performed in laboratory animal
model [7, 8] illustrate the properties of the Montanide Pet Gel A in various models. Three different
kinds of antigenic media are tested: puri fied protein as ovalbumin, inactivated virus and antigen
potentially more reactogenic like inactivated bacteria. The bacterial valence used in the dog trial is
composed of inactivated L.Icterohaemorrhagiae. This bacteria (Leptospira sp.) is a gram negative genius.
This type ofmicroorganism is lipopolysaccharide (LPS) containing and can be considered as a reactive
antigen [14]. There are no or very little reactions observed after injection of the antigenic media without
adjuvant: 1 dog out of 9 at the first injection and none of the cats. There is no impact of the vaccine
injection upon the general behaviour of any animal during the trials, whatever the adjuvant percentage
tested. No increase of the body temperature could be detect ed in the horse and dog models while during
the cat trial we observed a transient increase in body temperature induced by the Montanide based
vaccine. This increase was nevertheless not significant compared to both alum and control groups. The
general safety profile of the adjuvant used in all our trials is equivalent or improved compared to
aluminium salts, up to now considered as the golden standard in terms of adjuvant safety [9, 10]. The
safety profile observed in the cat and dog was worsened by the subcutaneous injection pathway: the local
oedemas induced are easily palpable and an intramuscular injection would reduce the negative impact of
local reaction. In the dog trial Montanide PET GEL A at 5% was presenting an equivalent macroscopic
safety profile compared to Alum based vaccine. In pets market, the macroscopic lesion or reactions linked
to the injection are unacceptable. Furthermore, the cat trial performed at a higher percentage of adjuvant
also indicated an improved safety profile of the Montanide based formulation compared to aluminium
based one [5]. The only differences observed were at the primo injection in the dog model: a faster
reaction to injection with Montanide PET GEL A at 5% compared to Alum based vaccine could be
observed. The local safety profile of those adjuvants based vaccines would be improved with vaccine
based only on viral antigens or by modification of the injection pathway (IM instead of SC). At last, no
evolution of the local reaction observed in all trials performed showed matter production or sterile
abscesses creat ed in the injection site. Safety at the injection site followed by histology performed upon
muscle or subcutaneous tissues biopsies (from the injection site) showed no significant differences
between the inflammatory properties ofMontanide based formula and aluminium based one. At last, no
evidence of larger adjuvant or vaccine remnants compared to aluminium based vaccine was found with
the gel based formulas. Dog and cats data collected are consistent upon the adjuvant metabolisation: they
demonstrate a discrete persistence of the adjuvant in the injected area at 43 to 120 days after vaccine
delivery. Neverthel ess, the induced inflammatory response is lower for the Montanide Pet Gel A based
formulation and more important: no chronic inflammatory process with Montanide PET GEL A could
be observed in any animal like it was the case for aluminium based formula. At last, the healing process
observed with Montanide based formula indicat es a short term strong inflammatory linked to an intense
immune response as numerous cells from the innate immune system (macrophages, monocytes) and
adaptive immune system (lymphocytes) can be identified in the inflammatory process infiltration of the
injected muscle. The choice of gram negative bacteria has certainly worsened the lesion observed at the
injection site during dog trial. The lipopolysaccharides from the cell wall of such genius are highly
reactogenic inducing strong response even without adjuvant as we observed in the dog biopsies. Safer
antigenic media will lead to lowering of necrosis and inflammatory process observed possibly allowing
increasing the ratio of adjuvant in the vaccine up to 7% as we did in the cat model. The antigen used for
the cat model presents weak infl ammatory properties as being 95% purifi ed protein. The safety profile
obtain during this trial being almost identical to the profile observed in the dog model, this finding
illustrates the balance between the antigenic inflammatory properties and the adjuvants ratio of use. Each
formulation will need to be assessed as a single case in terms of safety profile with a Montanide Pet
Gel A content from 5 to 7 %. Nevertheless, injection site safety profile observed is correlated to the
quantity of adjuvant used. Therefore, a speci fic care should be taken when calculating the optimal amount
of adjuvant in the vaccines balancing the safety profile with the effi cacy. Works illustrating the cellular
set of response induced by both aluminium salts and Montanide Pet Gel A in a relevant model would
bring some more information upon the immunoproperties and the differences between those adjuvants.
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The immune response directed to the bacterial valence of the dog and horse vaccine allowed to
discriminate the tested formula. The best results were obtained with Montanide PET GEL A at 5% with
100% of seroconversion and a suffici ent level to insure protection after 2 injections. The reference
adjuvant (aluminium) reached only 60% of seroconvertion. The cat model illustrated a higher antibody
response induced by the Montanide Pet Gel A based formulation, but the differences observed were not
significant. A larger number of individuals per groups will allow collecting more consistent data: the
results of the Montanide based formulation are deeply impacted by one of the animal presenting a very
weak response. Effi cacy of the vaccines in the horse model is still to collect. Nevertheless preliminary
data demonstrated a strong adjuvant effect after booster injection.
The high antibody titres observed in all models with the adjuvanted formulation will allow playing with
the antigen content in the vaccine, regulating the efficacy / safety vaccine’s balance. The formulation with
adjuvant can be designed with amount of antigen while having a maintained efficacy. Therefore the
inflammatory response in the injection site will be reduced. We need to collect long term immunological
data in order to observe any booster from natural infection occurring and correl ates those titers with the
farmer and veterinarian observations of horse health status. None of our study presents long term data
collection. Due to trial management we could not go longer than 150 days in horse test. This type of long
term study, remain to be started.
5. Conclusion
A synthetic pharmaceutical polymer has been tested in three different companion animals’ experimental
vaccines. In two out of these three experiments aluminium was used as the reference already used in
registered vaccines. In all cases, adjuvanted formulation gave a stronger and better response than antigen
alone, as well as more visible and acceptable reactions at the injection sites. Nevertheless, antibody titres
and expected prot ection are tremendously improved by the use ofMontanide PET GEL A. The design
ofmodern vaccines, containing different antigens obtained by conventional biotechnologies, but also
recombinant or live, can be effi ciently made by using robust and flexible synthetic GMP adjuvant.
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